Currax Drug Patent Portfolio

Currax owns 3 orange book drugs protected by 53 US patents Given below is the list of Currax's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10076614 Nasal delivery devices 20 Oct, 2034
Active
US10478574 Nasal administration 04 Nov, 2033
Active
US8978647 Nasal delivery 06 Dec, 2030
Active
US9649456 Nasal administration 21 Oct, 2030
Active
US8513299 Methods of using low-dose doxepin for the improvement of sleep 07 Sep, 2030
Active
US8899229 Powder delivery devices 18 Aug, 2030
Active
US8550073 Nasal delivery 22 Oct, 2029
Active
US10076615 Nasal delivery 30 Jul, 2029
Active
US9532971 Low-dose doxepin formulations and methods of making and using the same 01 Jun, 2029
Active
US10722667 Nasal administration 30 Dec, 2028
Active
US9107898 Methods of using low-dose doxepin for the improvement of sleep 01 May, 2028
Active
US10548871 Low-dose doxepin formulations and methods of making and using the same 11 Apr, 2028
Active
US11096920 Low-dose doxepin formulations and methods of making and using the same 11 Apr, 2028
Active
US9907780 Low-dose doxepin formulations and methods of making and using the same 11 Apr, 2028
Active
US8875704 Nasal administration 07 Apr, 2028
Active
US11234954 Low-dose doxepin for treatment of sleep disorders in elderly patients 18 Jan, 2028
Active
US10398859 Nasal delivery devices 19 Dec, 2027
Active
US7915307 Methods of improving the pharmacokinetics of doxepin 24 Aug, 2027
Active
US10653660 Methods of improving the pharmacokinetics of doxepin 20 Jul, 2027
Active
US11110074 Methods of improving the pharmacokinetics of doxepin 20 Jul, 2027
Active
US9572814 Methods of improving the pharmacokinetics of doxepin 20 Jul, 2027
Active
US10238620 Methods of using low-dose doxepin for the improvement of sleep 18 May, 2027
Active
US10653662 Methods of using low-dose doxepin for the improvement of sleep 18 May, 2027
Active
US9486437 Methods of using low-dose doxepin for the improvement of sleep 18 May, 2027
Active
US9861607 Methods of using low-dose doxepin for the improvement of sleep 18 May, 2027
Active
US10124132 Nasal delivery 06 Mar, 2027
Active
US7332183 Multilayer dosage forms containing NSAIDs and triptans 02 Apr, 2026
Active
US11571531 Powder delivery devices 23 Feb, 2026
Active
US7332183 Multilayer dosage forms containing NSAIDs and triptans 02 Oct, 2025
Active
US8590530 Nasal delivery devices 15 Sep, 2025
Active
US9108015 Nasal delivery devices 15 Sep, 2025
Active
US7975690 Nasal devices 18 Aug, 2025
Active
US9119932 Nasal delivery device 23 Apr, 2024 Expired
US8327844 Nasal delivery method 03 Oct, 2023 Expired
US8047202 Nasal devices 02 Jul, 2023 Expired
US6715485 Nasal delivery device 03 Mar, 2020 Expired
US8555877 Nasal delivery device 03 Mar, 2020 Expired
US6211229 Treatment of transient and short term insomnia 17 Feb, 2020 Expired
US5872145 Formulation of 5-HT agonist and NSAID for treatment of migraine 14 Feb, 2018 Expired
US6060499 Anti-migraine methods and compositions using 5-HT agonists with long-acting NSAIDs 14 Feb, 2018 Expired
US6586458 Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs 14 Feb, 2018 Expired
US8022095 Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs 14 Feb, 2018 Expired
US5872145 Formulation of 5-HT agonist and NSAID for treatment of migraine 14 Aug, 2017 Expired
US6060499 Anti-migraine methods and compositions using 5-HT agonists with long-acting NSAIDs 14 Aug, 2017 Expired
US6586458 Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs 14 Aug, 2017 Expired
US8022095 Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs 14 Aug, 2017 Expired
US5585115 Pharmaceutical excipient having improved compressability 09 Jan, 2015 Expired
US5725884 Pharmaceutical excipient having improved compressibility 09 Jan, 2015 Expired
US5866166 Pharmaceutical excipient having improved compressibility 09 Jan, 2015 Expired
US5948438 Pharmaceutical formulations having improved disintegration and/or absorptivity 09 Jan, 2015 Expired
US6103219 Pharmaceutical excipient having improved compressibility 09 Jan, 2015 Expired
US6217909 Pharmaceutical excipient having improved compressibility 09 Jan, 2015 Expired
US5502047 Treatment for insomnia 26 Mar, 2013 Expired


Given below is the list of recent legal activities going on the following drug patents of Currax.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 8th Yr, Small Entity 19 Jun, 2024 US9532971
Payment of Maintenance Fee, 8th Yr, Small Entity 24 Apr, 2024 US9486437
Payment of Maintenance Fee, 4th Year, Large Entity 10 Jan, 2024 US10722667
Payment of Maintenance Fee, 4th Yr, Small Entity 01 Nov, 2023 US10653662
Payment of Maintenance Fee, 4th Yr, Small Entity 01 Nov, 2023 US10653660
Payment of Maintenance Fee, 4th Yr, Small Entity 19 Jul, 2023 US10548871
Payment of Maintenance Fee, 4th Year, Large Entity 19 May, 2023 US10478574
Payment of Maintenance Fee, 12th Year, Large Entity 26 Apr, 2023 US8047202
Payment of Maintenance Fee, 8th Year, Large Entity 15 Feb, 2023 US9119932
Payment of Maintenance Fee, 4th Year, Large Entity 15 Feb, 2023 US10398859
Recordation of Patent Grant Mailed 07 Feb, 2023 US11571531
Patent Issue Date Used in PTA Calculation 07 Feb, 2023 US11571531
Payment of Maintenance Fee, 8th Year, Large Entity 01 Feb, 2023 US9108015
Payment of Maintenance Fee, 8th Yr, Small Entity 01 Feb, 2023 US9107898
Email Notification 19 Jan, 2023 US11571531


Currax's Drug Patent Litigations

Currax's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Aug 08, 2011, against patent number US8513299. The petitioner , challenged the validity of this patent, with Roberta L. Rogowski et al as the respondent. Click below to track the latest information on how companies are challenging Currax's patents.

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US7332183 November, 2015 Terminated-Denied
(06 May, 2016)
POZEN Inc. Graybar Pharmaceuticals, LLC
US8513299 August, 2011 Decision
(07 Dec, 2012)
Roberta L. Rogowski et al


Currax Drug Patents' Oppositions Filed in EPO

Currax drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Sep 27, 2005, by Direct-Haler A/S. This opposition was filed on patent number EP00906570A. Click below to reveal the latest opposition data.


Application Filing Date Opposition Party Legal Status
Patent litigations
EP08736896A Jun, 2021 Beck Greener LLP Patent maintained as amended
EP13715145A Sep, 2020 ELKINGTON AND FIFE LLP Granted and Under Opposition
EP00906570A Sep, 2005 Direct-Haler A/S Opposition rejected


Currax's Family Patents

Currax drugs have patent protection in a total of 32 countries. It's US patent count contributes only to 33.4% of its total global patent coverage. 5 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree.

Family Patents



Currax Drug List

Given below is the complete list of Currax's drugs and the patents protecting them.


1. Onzetra Xsail

Onzetra Xsail is protected by 20 patents, out of which 5 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10076614 Nasal delivery devices 20 Oct, 2034
(10 years from now)
Active
US10478574 Nasal administration 04 Nov, 2033
(9 years from now)
Active
US8978647 Nasal delivery 06 Dec, 2030
(6 years from now)
Active
US9649456 Nasal administration 21 Oct, 2030
(6 years from now)
Active
US8899229 Powder delivery devices 18 Aug, 2030
(5 years from now)
Active
US8550073 Nasal delivery 22 Oct, 2029
(5 years from now)
Active
US10076615 Nasal delivery 30 Jul, 2029
(4 years from now)
Active
US10722667 Nasal administration 30 Dec, 2028
(4 years from now)
Active
US8875704 Nasal administration 07 Apr, 2028
(3 years from now)
Active
US10398859 Nasal delivery devices 19 Dec, 2027
(3 years from now)
Active
US10124132 Nasal delivery 06 Mar, 2027
(2 years from now)
Active
US11571531 Powder delivery devices 23 Feb, 2026
(1 year, 4 months from now)
Active
US8590530 Nasal delivery devices 15 Sep, 2025
(10 months from now)
Active
US9108015 Nasal delivery devices 15 Sep, 2025
(10 months from now)
Active
US7975690 Nasal devices 18 Aug, 2025
(10 months from now)
Active
US9119932 Nasal delivery device 23 Apr, 2024
(5 months ago)
Expired
US8327844 Nasal delivery method 03 Oct, 2023
(1 year, 12 days ago)
Expired
US8047202 Nasal devices 02 Jul, 2023
(1 year, 3 months ago)
Expired
US6715485 Nasal delivery device 03 Mar, 2020
(4 years ago)
Expired
US8555877 Nasal delivery device 03 Mar, 2020
(4 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Onzetra Xsail's drug page


2. Silenor

Silenor is protected by 23 patents, out of which 8 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8513299 Methods of using low-dose doxepin for the improvement of sleep 07 Sep, 2030
(5 years from now)
Active
US9532971 Low-dose doxepin formulations and methods of making and using the same 01 Jun, 2029
(4 years from now)
Active
US9107898 Methods of using low-dose doxepin for the improvement of sleep 01 May, 2028
(3 years from now)
Active
US10548871 Low-dose doxepin formulations and methods of making and using the same 11 Apr, 2028
(3 years from now)
Active
US11096920 Low-dose doxepin formulations and methods of making and using the same 11 Apr, 2028
(3 years from now)
Active
US9907780 Low-dose doxepin formulations and methods of making and using the same 11 Apr, 2028
(3 years from now)
Active
US11234954 Low-dose doxepin for treatment of sleep disorders in elderly patients 18 Jan, 2028
(3 years from now)
Active
US7915307 Methods of improving the pharmacokinetics of doxepin 24 Aug, 2027
(2 years from now)
Active
US10653660 Methods of improving the pharmacokinetics of doxepin 20 Jul, 2027
(2 years from now)
Active
US11110074 Methods of improving the pharmacokinetics of doxepin 20 Jul, 2027
(2 years from now)
Active
US9572814 Methods of improving the pharmacokinetics of doxepin 20 Jul, 2027
(2 years from now)
Active
US10238620 Methods of using low-dose doxepin for the improvement of sleep 18 May, 2027
(2 years from now)
Active
US10653662 Methods of using low-dose doxepin for the improvement of sleep 18 May, 2027
(2 years from now)
Active
US9486437 Methods of using low-dose doxepin for the improvement of sleep 18 May, 2027
(2 years from now)
Active
US9861607 Methods of using low-dose doxepin for the improvement of sleep 18 May, 2027
(2 years from now)
Active
US6211229 Treatment of transient and short term insomnia 17 Feb, 2020
(4 years ago)
Expired
US5585115 Pharmaceutical excipient having improved compressability 09 Jan, 2015
(9 years ago)
Expired
US5725884 Pharmaceutical excipient having improved compressibility 09 Jan, 2015
(9 years ago)
Expired
US5866166 Pharmaceutical excipient having improved compressibility 09 Jan, 2015
(9 years ago)
Expired
US5948438 Pharmaceutical formulations having improved disintegration and/or absorptivity 09 Jan, 2015
(9 years ago)
Expired
US6103219 Pharmaceutical excipient having improved compressibility 09 Jan, 2015
(9 years ago)
Expired
US6217909 Pharmaceutical excipient having improved compressibility 09 Jan, 2015
(9 years ago)
Expired
US5502047 Treatment for insomnia 26 Mar, 2013
(11 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Silenor's drug page


3. Treximet

Treximet is protected by 10 patents, out of which 8 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US7332183
(Pediatric)
Multilayer dosage forms containing NSAIDs and triptans 02 Apr, 2026
(1 year, 5 months from now)
Active
US7332183 Multilayer dosage forms containing NSAIDs and triptans 02 Oct, 2025
(11 months from now)
Active
US5872145
(Pediatric)
Formulation of 5-HT agonist and NSAID for treatment of migraine 14 Feb, 2018
(6 years ago)
Expired
US6060499
(Pediatric)
Anti-migraine methods and compositions using 5-HT agonists with long-acting NSAIDs 14 Feb, 2018
(6 years ago)
Expired
US6586458
(Pediatric)
Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs 14 Feb, 2018
(6 years ago)
Expired
US8022095
(Pediatric)
Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs 14 Feb, 2018
(6 years ago)
Expired
US5872145 Formulation of 5-HT agonist and NSAID for treatment of migraine 14 Aug, 2017
(7 years ago)
Expired
US6060499 Anti-migraine methods and compositions using 5-HT agonists with long-acting NSAIDs 14 Aug, 2017
(7 years ago)
Expired
US6586458 Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs 14 Aug, 2017
(7 years ago)
Expired
US8022095 Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs 14 Aug, 2017
(7 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Treximet's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List